Brad Margus is the founder of Cerevance. Cerevance has raised $204M in total funding. Latest round: Series B. Based in San Francisco, CA.
Brad Margus is a serial biopharma entrepreneur and the Co-founder and Board Chair of Cerevance, a clinical-stage company developing novel therapeutics for brain diseases. He previously founded Perlegen and Envoy, bringing decades of experience in drug discovery and commercialization. Cerevance, founded in late 2016, focuses on profiling human brain tissue to identify cell-type-specific drug targets for disorders like Parkinson’s disease.
Full founder directory · Investor directory · Company funding database · Fundraising library